Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Income from Continuing Operations (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Income from Continuing Operations for 7 consecutive years, with 97988000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 21.25% to 97988000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 349769000.0, a 33.56% decrease, with the full-year FY2025 number at 349769000.0, down 33.56% from a year prior.
  • Income from Continuing Operations was 97988000.0 for Q4 2025 at Kymera Therapeutics, down from 92618000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 13193000.0 in Q1 2021 to a low of 97988000.0 in Q4 2025.
  • A 5-year average of 54264666.67 and a median of 48183500.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 49.95% in 2023, then plummeted 317.34% in 2024.
  • Kymera Therapeutics' Income from Continuing Operations stood at 24759000.0 in 2021, then crashed by 56.27% to 38690000.0 in 2022, then skyrocketed by 49.95% to 19364000.0 in 2023, then tumbled by 317.34% to 80814000.0 in 2024, then fell by 21.25% to 97988000.0 in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Income from Continuing Operations are 97988000.0 (Q4 2025), 92618000.0 (Q3 2025), and 84665000.0 (Q2 2025).